Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Ocular Criteria~* RP, typical forms(i.e. elevated final dark adaptation threshold,retinal arteriolar narrowing,and reduced and delayed full-field ERGs).~* Best-corrected visual acuity 20/100 or better~* HFA program 30-2 total point score \>= 250 decibels(dB)to a size V white test light~* No confounding ocular disease such as glaucoma,uveitis,diabetic retinopathy,posterior subcapsular cataract more than 11% of total lens area (ie equivalent to P3 on Lens Opacity Classification System III)and pupil diameter after dilation less than 6 mm.~Dietary Criteria~* Fruit and vegetable intake \< 10 servings/d~* Spinach or kale intake \< 1 serving/d, i.e. \<1/2 cup of cooked spinach or kale per day~* Dietary lutein intake \<=5.4 mg/d as estimated from food frequency questionnaire~* No intake of cod liver oil or omega-3 capsules~* Dietary preformed vitamin A intake \<= 10,000 IU/d~* Supplement intake \<= 5,000 IU/d of Vitamin A and \<= 30 IU/d of Vitamin E~* Consumption \<= 3 alcoholic beverages/d~Medical and other criteria~* Age 18-60 y~* Body mass index \< 40 and weight \>= 5th percentile for age,gender,and height~* Serum retinol level \<= 100 micrograms/deciliter and serum retinyl ester level \<= 380 nanomoles/Liter~* Serum cholesterol \< 300 micrograms/deciliter and serum triglyceride level \<400 micrograms/deciliter~* No clinically significant abnormality on blood cell count, glucose level, blood urea nitrogen level, serum lipid panel results or serum liver function profile.~* Not pregnant or planning to become pregnant~* Not smoking currently~* Agreed not to know tablet content or course of condition until the end of the trial.~* No other disease which might affect absorption or metabolism of lutein or vitamin A.~* Only one patient per family was accepted into the study.~Exclusion Criteria:~* Women who are pregnant or planning to become pregnant (Vitamin A supplements can increase the risk of birth defects.)~* Current participation in another clinical trial for RP~* Patients with atypical forms such as paravenous RP, pericentral RP, sector RP,unilateral RP,Refsum disease, Bardet-Biedl syndrome, retinitis punctata albescens and cone-rod dystrophy were excluded as were patients with RP and profound congenital deafness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lutein plus 15,000 IU/d Vitamin A (Type: EXPERIMENTAL): Daily intake of 12mg of Lutein plus 15,000 IU/d of Vitamin A palmitate
- Control plus 15,000 IU/d Vitamin A (Type: PLACEBO_COMPARATOR): Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate

Based on this trial design, predict the completion outcome and termination type (if applicable).